Butensky & Cohen Financial Security Inc. Purchases 1,947 Shares of Johnson & Johnson (NYSE:JNJ)

Butensky & Cohen Financial Security Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,632 shares of the company's stock after purchasing an additional 1,947 shares during the quarter. Butensky & Cohen Financial Security Inc.'s holdings in Johnson & Johnson were worth $3,996,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of JNJ. Pacer Advisors Inc. raised its stake in shares of Johnson & Johnson by 15.3% in the second quarter. Pacer Advisors Inc. now owns 240,605 shares of the company's stock valued at $35,167,000 after acquiring an additional 31,908 shares during the last quarter. Sei Investments Co. raised its position in Johnson & Johnson by 10.7% in the 2nd quarter. Sei Investments Co. now owns 1,126,658 shares of the company's stock valued at $164,672,000 after purchasing an additional 109,205 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Johnson & Johnson by 31.8% in the second quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company's stock worth $238,951,000 after purchasing an additional 394,518 shares in the last quarter. Kiely Wealth Advisory Group Inc. increased its stake in shares of Johnson & Johnson by 5.7% in the second quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company's stock valued at $296,000 after buying an additional 99 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its holdings in shares of Johnson & Johnson by 30.7% in the second quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company's stock valued at $6,712,000 after buying an additional 10,789 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JNJ. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE JNJ traded down $0.74 during midday trading on Friday, reaching $147.03. 10,678,393 shares of the stock were exchanged, compared to its average volume of 6,880,262. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a 50-day simple moving average of $148.51 and a two-hundred day simple moving average of $156.03.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson's payout ratio is 71.78%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.